Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 28, 2025

Kinross Gold and Carter's have been highlighted as Zacks Bull and Bear of the Day

View original at nasdaq.com
Kinross Gold and Carter's have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – November 28, 2025 – Zacks Equity Research shares Kinross Gold KGC, as the Bull of the Day and, Carter’s CRI, as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Kinross Gold has Zacks Rank #1 (Strong Buy) rating

    80% confidence
  • Kinross is expected to grow earnings at 40.85% annually over the next three to five years

    80% confidence
  • Coca-Cola expects the number of billion-dollar brands to keep growing

    80% confidence
  • Coca-Cola stock carries Zacks Rank #3 (Hold)

    80% confidence
  • Zacks Earnings ESP forecasting potential 38.84% earnings beat for Kinross in upcoming report

    80% confidence
  • Carter's sales expected to decline 0.15% in 2025, followed by only 1.71% rebound in 2026

    80% confidence
  • Carter's has Zacks Rank #5 (Strong Sell) rating

    80% confidence
  • Kinross trades at only 16.5x forward earnings with PEG ratio of 0.4

    80% confidence
  • Zacks Consensus Estimate for Coca-Cola's 2025 and 2026 EPS implies year-over-year growth of 3.5% and 8% respectively

    80% confidence
  • Since 2000, Zacks' top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    80% confidence
  • Carter's key resistance level to watch is $33.40 for potential breakout

    80% confidence
  • Coca-Cola has almost 30 billion-dollar brands accounting for nearly one-quarter of all billion-dollar brands in the industry

    80% confidence
  • Quantum Computing is the next technological revolution and could be even more advanced than AI

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com